EVRULEUCEL
UNII 35C6UF9WLP

Substance Identification & Data

This profile provides standardized clinical and technical data for Evruleucel, uniquely identified by the FDA Unique Ingredient Identifier (UNII) 35C6UF9WLP.

Technical mappings include the Chemical Abstracts Service (CAS) Registry Number N/A and the RxNorm Concept ID (RxCUI) N/A. Explore the sections below for detailed nomenclature and a complete directory of NDC-listed products containing this ingredient.

FDA UNII Code

35C6UF9WLP

CAS Registry Number

N/A

RxNorm Concept ID

N/A

Detailed Substance Profile

Preferred Name

EVRULEUCEL

Official standardized name for this substance within the FDA UNII nomenclature system.

NCI Thesaurus

C199046

National Cancer Institute reference terminology for clinical and research data.

INN ID

12468

Sequential identifier assigned via the WHO International Nonproprietary Name program.

USAN ID

KL-176

Identifier assigned by the United States Adopted Names Council.

Substance Type

structurallyDiverse

ISO 11238 classification category (e.g., Chemical, Polymer, Protein).

ITIS TSN

180092

Taxonomic Serial Number for species identified in the Integrated Taxonomic Information System.

NCBI Taxonomy

9606

Unique numeric identifier used to specify biological species in the NCBI database.

Synonyms and Nomenclature

This section provides a complete list of nomenclature and identifier mappings for Evruleucel. Identifiers are organized into official regulatory terms, commercial trade names, and technical systematic synonyms used to ensure accurate identification across clinical pharmaceutical databases, regulatory filings, and electronic health records.

FDA Official Name

EVRULEUCEL

Common Names & Synonyms

ALLOGENEIC CYTOTOXIC T LYMPHOCYTES THAT ARE DERIVED FROM PERIPHERAL BLOOD MONONUCLEAR CELLS (PBMCS) FROM HEALTHY EPSTEIN-BARR VIRUS (EBV) SEROPOSITIVE DONORS AND HAVE BEEN TRANSDUCED WITH A VIRAL VECTOR EXPRESSING LATENT MEMBRANE PROTEIN 1 (LMP1), LMP2, AND EBV NUCLEAR ANTIGEN 1 (EBNA1). PBMCS ARE THAWED AND A PORTION OF THESE CELLS ARE INCUBATED WITH A REPLICATION-DEFICIENT ADENOVIRUS ENCODING A TRANSGENE THAT EXPRESSES AN EBV POLYEPITOPE PROTEIN TO PRODUCE ANTIGEN-PRESENTING CELLS (APCS). THESE APCS ARE IRRADIATED TO ARREST THEIR REPLICATION AND THEN ADDED TO THE REMAINING PBMCS TO STIMULATE AND INDUCE THE EXPANSION OF EBV-SPECIFIC T-CELLS THAT CAN TARGET EBV TRANSFORMED B LYMPHOCYTES

EVRULEUCEL [INN]

EVRULEUCEL [USAN]

EVRULEUCEL [WHO-DD]